CATALYSTYahoo Finance • 23h ago
Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?Yahoo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
Why TKNO Stock dropped -4.75% Today — RQD Quant Desk Flash
$7.01 -4.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.94
Alpha Teknova Inc. (TKNO) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $454.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TKNO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TKNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Alpha Teknova Inc. (NASDAQ: TKNO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $7.01 (-4.75% 1D, market cap $454.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TKNO ranks #422 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TKNO compare to NNNN and MYGN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TKNO carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 33.2%, and ROIC of -21.3%. By comparison, NNNN (Anbio Biotechnology (Class A)) holds a D- grade (35/100 RQD, P/E 83.6x, ROIC 17.0%, cap $483.5M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TKNO?
▼
Per TKNO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850902), Alpha Teknova Inc. generated $40.5M in revenue (+7.4% YoY), -$17.3M in net income, and -$9.8M in free cash flow against $103.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.94 (-1.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TKNO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY TKNO SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (33% of score)
Altman Z-Score 6.93 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$8.22-10.1% Next Q
50
Q2 (-2Q)Grade D$7.39-3.8% Next Q
47
Q3 (-1Q)Grade D$7.11-1.4% Next Q
45
CurrentGrade D-$7.01-7% Hist 90D α
42
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TKNO Turnaround Squeeze
While TKNO currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.73) and Max Pain ($7.36) forces dealer call-delta covering toward $9.95.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TKNO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TKNO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TKNO Stock dropped -4.75% Today — RQD Quant Desk Flash
Alpha Teknova Inc. (TKNO) dropped -4.75% to $7.01, trading at 67% of its 52-week range ($1.91 – $9.48). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 67% of its 52-week range ($1.91 – $9.48) with RSI-14 at 48.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.01 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 33.2% gross margin and $0 annual free cash flow.
Live TKNO Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
Alpha Teknova(TKNO) Stock Options Chain | Quotes & NewsMoomoo report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Alpha Teknova stock tumbles on public offering announcementYahoo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Alpha Teknova Prices 8.0M-Share Offering at $5.00 for $40 Million; TD Securities, William Blair LeadTradingView report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBigGo Finance • 1d ago
Alpha Teknova Shares Plunge 23% After $5-a-Share Stock SaleBigGo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Teknova TKNO Announces Proposed Public Offering of Common StockQuiver Quantitative report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHkalkine.ca • 1d ago
Did Investors Miss the Offering Behind Alpha Teknova (NASDAQ:TKNO) Penny Stock's 33% Plunge Despite a Strong Preliminary Quarter?kalkine.ca report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Full-Year Revenue Guidance Hike Drove Alpha Teknova (TKNO) HigherConestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. Conestoga Capital Advisors released its third-quarter 2026 investor letter, out
MARKET WIRESeekingAlpha • 4d ago
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And SellsConestoga Micro Cap Composite reports 3Q26 performance highlights and portfolio adjustments. Review the latest leadership and laggard insights here.
MARKET WIREBenzinga • 12d ago
Tesla, Lam Research, Rollins And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionU.S. stock futures fell as Tesla dropped 5.4% despite beating Q3 estimates; NVE, Cypherpunk, Lam Research and others also declined premarket.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TKNO)
- ✓Walkthrough of TKNO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TKNO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +95.26%▲ ASCENDING CHANNEL
2026-11-03O $8.09H $8.09L $7.01C $7.01VOL 651.1K
RES: $10.71SUP: $5.07SMA50: $7.73SMA200: $4.93
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TKNO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on TKNO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TKNO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TKNO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TKNO)
Health Care Rank #422 of 1015
⚔️ NNNN vs TKNO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TKNO vs. NNNN, MYGN, ACHV, QDEL)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Alpha Teknova Inc. (TKNO) ranks #422 by composite RQD confidence (42/100, grade D-) and #459 by equity capitalization ($454.1M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with TKNO at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TKNO
ACTIVE
Alpha Teknova Inc. | D- | 42/100 | — | 33.2% | -21.3% | -4.75% | $454.1M | Benchmark Subject |
| NNNN Anbio Biotechnology (Class A) | D- | 35/100 | 83.6x | 87.2% | 17.0% | +4.46% | $483.5M | /nnnn-vs-tkno → |
| MYGN Myriad Genetics Inc. | D | 47/100 | — | 69.9% | -35.0% | -7.87% | $607.4M | /mygn-vs-tkno → |
| ACHV Achieve Life Sciences Inc. | D- | 39/100 | — | — | -35.0% | -3.22% | $702.8M | /achv-vs-tkno → |
| QDEL QuidelOrtho Corporation | E | 21/100 | — | — | -35.0% | +5.89% | $908.6M | /qdel-vs-tkno → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850902 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alpha Teknova Inc. (TKNO) reported GAAP revenue of $40.5M (+7.4% vs. FY2024 revenue of $37.7M , and +10.5% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$8.6M, and free cash flow of -$9.8M (+27.5% YoY). On the balance sheet, TKNO closed FY2025 with $103.6M in total assets against $0 in total debt (Altman Z-Score: 6.93, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.5M | -$17.3M | -$8.6M | -$9.8M | $103.6M | — |
| FY2024 (FY) | 2024-12-31 | $37.7M | -$26.7M | -$12.4M | -$13.5M | $118.8M | — |
| FY2023 (FY) | 2023-12-31 | $36.7M | -$36.8M | -$18.8M | -$18.8M | — | — |
3. TKNO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TKNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Alpha Teknova Inc. (NASDAQ: TKNO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $7.01 (-4.75% 1D, market cap $454.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TKNO ranks #422 in composite RQD confidence.
How does TKNO compare to NNNN and MYGN in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TKNO carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 33.2%, and ROIC of -21.3%. By comparison, NNNN (Anbio Biotechnology (Class A)) holds a D- grade (35/100 RQD, P/E 83.6x, ROIC 17.0%, cap $483.5M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TKNO?
Per TKNO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850902), Alpha Teknova Inc. generated $40.5M in revenue (+7.4% YoY), -$17.3M in net income, and -$9.8M in free cash flow against $103.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TKNO trading relative to its 50-day, 200-day, and 52-week technical levels?
TKNO last traded at $7.01 (-4.75% on volume of 517,242 shares), positioning the stock -9.31% below its 50-day simple moving average ($7.73) and +42.19% above its 200-day simple moving average ($4.93). Across its 52-week range of $1.91 to $9.48, TKNO sits at the 67.4% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.13 to $7.89).
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ SEC XBRL & RQD VERIFIED
TKNO — Alpha Teknova Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Alpha Teknova Inc. (TKNO) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.01 (-4.75% 1D, market capitalization $454.1M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -21.3%, gross margin of 33.2%, operating margin of -41.9%, and free cash flow yield of -1.96%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 6.93, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Alpha Teknova Inc. (TKNO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $0.5B. — describes its specific products, customers, or revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Alpha Teknova Inc. (TKNO) reported $40.5M in annual revenue (up from $37.7M in FY2024, +7.4% YoY) and -$17.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.7M revenue, -$36.8M net income) through FY2025, TKNO scaled operating cash flow to -$8.6M and free cash flow to -$9.8M, backed by $103.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.96% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $1.91 – $9.48 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -41.9% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), TKNO carries a macro regime beta of 1.00 and gross margin of 33.2%.
- Key Question #1: Can TKNO sustain or expand its -41.9% operating margin and -21.3% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $40.5M and free cash flow of -$9.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is TKNO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
TKNO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Alpha Teknova Inc. (TKNO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 23h ago
Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar? Yahoo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Alpha Teknova(TKNO) Stock Options Chain | Quotes & News Moomoo report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Alpha Teknova stock tumbles on public offering announcement Yahoo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Alpha Teknova Prices 8.0M-Share Offering at $5.00 for $40 Million; TD Securities, William Blair Lead TradingView report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE BigGo Finance • 1d ago
Alpha Teknova Shares Plunge 23% After $5-a-Share Stock Sale BigGo Finance report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Teknova TKNO Announces Proposed Public Offering of Common Stock Quiver Quantitative report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH kalkine.ca • 1d ago
Did Investors Miss the Offering Behind Alpha Teknova (NASDAQ:TKNO) Penny Stock's 33% Plunge Despite a Strong Preliminary Quarter? kalkine.ca report covering Alpha Teknova Inc. (TKNO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 4d ago
Full-Year Revenue Guidance Hike Drove Alpha Teknova (TKNO) Higher Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. Conestoga Capital Advisors released its third-quarter 2026 investor letter, out
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TKNO Bull vs. Bear Conversation Board — What's Your Call at $7.01?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TKNO 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $8.54 (+16.0%)
📌 Pinned Debate Revenue grew from $36.7M in FY 2023 to $40.5M in FY 2025 while the Forensic Balance Sheet pillar scored 14/20 with Altman Z of 6.93.
Picked up a starter position in TKNO in my $100K Virtual Cash book at $7.36. Revenue grew from $36.7M in FY 2023 to $40.5M in FY 2025 while the Forensic Balance Sheet pillar scored 14/20 with Altman Z of 6.93.. Trading inside a $1.91–$9.48 52-week range with -1.96% FCF yield gives solid downside support if Biotechnology: In Vitro & In Vivo Diagnostic Substances multiples expand this quarter.
ArenaChamp_24 🐂 BULL
@TapeReader_Pro Agree on the RQD 42/100 quality, though with 1.0 beta I'm scaling in with half-size at $7.36 and keeping dry powder in case we test $6.84.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $6.18 (-16.0%)
Spot @ $7.36 ROIC of -21.3%, FCF yield of -1.96%, and an 8.0M-share offering at $5.00 signal continued cash burn and dilution risk.
Here is the bear case nobody on the bull side wants to address on TKNO: ROIC of -21.3%, FCF yield of -1.96%, and an 8.0M-share offering at $5.00 signal continued cash burn and dilution risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: In Vitro & In Vivo Diagnostic Substances triggers a 12-15% air pocket.